XClinical GmbH starts cooperation with the academic research networks "Society for Paediatric Oncology and Haematology"

XClinical GmbH starts cooperation with the academic research networks "Society for Paediatric Oncology and Haematology" (GPOH) and the "Hannover Clinical Trial Center" (HCTC).

(firmenpresse) - XCLINICAL GMBH, Munich, Germany - August 31, 2009 - XClinical, a European vendor of software products for eClinical trials, known for its innovative and user-friendly CDISC ODM certified EDC software suite MARVIN, today announced that the academic research network GPOH (Gesellschaft für Pädiatrische Onkologie und Hämatologie) and the contract research organisation HCTC (Hannover Clinical Trial Center) chose XClinical's EDC Software MARVIN.

GPOH will start using the software solution in one registry and three clinical trials which explore various types of cancer in children and adolescents. In the medium term it is planned to record most children suffering from malignant diseases and blood diseases in MARVIN. "Due to the new legal requirements on investigator initiated trials, we looked for a validated system which we found in XClinical's solution. A further important argument is, that XClinical is experienced in the combination of complex registries with clinical trials in the same database which is proved by the AFNET in cooperation with the competence network for atrial fibrillation." Stated Dipl. Inf. Andrea Barth, Head of Data Management at GPOH.

HCTC selected MARVIN for the same reasons. "Furthermore we have been convinced by the system's user-friendliness. Also XClinical's active membership in the CDISC organization has been an important argument." Said Prof. Dr. von der Leyen, CEO at HCTC. They will start using MARVIN in two large therapy optimization trials for the treatment of different forms of hepatitis in Germany and Europe, respectively. These studies will be performed in cooperation with the Competence Network for Viral Hepatitis (Hep-Net, Kompetenznetz Hepatitis), the main project of the German Liver Foundation. Hep-Net supports the nationwide research of viral hepatitis and helps to develop uniform diagnostic and therapeutic standards for the therapy of hepatitis in Germany.

Suggested Articles

Inovio CEO J. Joseph Kim is undeterred by short sellers and other detractors who doubt his company can shuttle a COVID-19 DNA vaccine to market.

Adding entinostat to hormone therapy did not help patients with HR-positive, HER2-negative breast cancer live longer.

The data add to the evidence in support of the IL-6 drug ahead of a FDA decision to approve it in a rare disease served by Alexion’s Soliris.